Taylor, J. A., Joshi, S., Satkunasivam, R., Dickstein, R. J., Salmasi, A., Lotan, Y., Johnson, S., Pruthi, R., Tosone, C., Schuckman, A. K., Liu, J. (2025). Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.802